Products
Erlizumab Biosimilar Monoclonal Antibody (CD18) for Research
Cat No.: GMP-Bios-INN-844
Anti-ITGB2 therapeutic antibody (Pre-made Erlizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab was developed by Genentech under a partnership with Roche to treat heart attack, stroke, and traumatic shock.[1]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-844-1mg | 1mg | 3090 |
| GMP-Bios-INN-844-10mg | 10mg | |
| GMP-Bios-INN-844-100mg | 100mg | |
| GMP-Bios-INN-844-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Erlizumab Biosimilar, Whole Mab, Anti-Itgb2 Antibody: Anti-CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody |
| INN Name | Erlizumab |
| Target | ITGB2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - nd |
| VD LC | IgG1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | 0 |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
